icon on Peptides are going mainstream, and so is regulatory scrutiny. As demand grows, boards, inspectors, and even plaintiffs’ attorneys are leaning heavily on USP <795> and <797> to judge safety and compliance.
For peptide operators, gaps in documentation, BUD support, training, and workflow design are becoming major risk points. Staying ahead of USP expectations is no longer optional. it's essential for protecting your business as the market matures.
Read the full article by Alex Leonowicz here: https://bit.ly/4rmN4Us